2256 — Abbisko Medicine Share News
0.000.00%
Last trade - 00:00- HK$4.55bn
- HK$2.21bn
- CNY612.12m
Brief: Abbisko Cayman Sees HY Profit RMB200 Mln To RMB220 Mln
Brief: Abbisko Cayman H1 Revenue RMB 497 Million
Brief: Abbisko Cayman Ltd Says On-Market Share Repurchase
Brief: Abbisko Cayman Says FGFR4 Inhibitor Irpagratinib Granted ODD By FDA
Brief: Abbisko Cayman Says On-Market Share Repurchase
Brief: Abbisko Cayman Posts Loss Attributable For Year RMB431.6 Mln
Brief: Abbisko Cayman Says Unit Received Upfront Payment Of $70 Mln for Licensing Deal
Brief: Abbisko Cayman Says CSF-1R Inhibitor Pimicotinib Granted Fast Track Designation By U.S. FDA
Brief: Abbisko Cayman Reaches License Agreement With Merck For Pimicotinib
Brief: Abbisko Cayman Says Cd73 Inhibitor Absk051 Obtains IND Approval From NMPA
Brief: Abbisko Cayman Says Fgfr4 Mutant Inhibitor- Absk012 Obtained Clinical Study Approval From U.S. FDA
Brief: Abbisko Cayman Says IND Approval By NMPA Obtained For Absk112
Brief: Abbisko Cayman Says Absk011 Hcc Combo Clinical Trial Approved By NMPA
Brief: Abbisko Cayman Says Absk021 Phase Iii Tgct Clinical Trial Approved By EMA
Brief: Abbisko Cayman Clarifies Founders Have Not Disposed Of Any Shares Of Company
Brief: Abbisko Cayman Posts HY Loss Attributable RMB140.1 Million
Brief: Abbisko Cayman Says EGFR Exon20ins Inhibitor Absk112 Received Clinical Trial Approval From FDA
Brief: Abbisko Cayman Says CSF-1R Inhibitor Pimicotinib Granted Priority Medicine Designation
Brief: Abbisko Cayman Says FGFR4 Mutant Inhibitor ABSK012 Granted Orphan Drug Designation By U.S. FDA